Literature DB >> 21524387

Identification and functions of the plasma membrane receptor for thyroid hormone analogues.

Hung-Yun Lin1, Vivian Cody, Faith B Davis, Aleck A Hercbergs, Mary K Luidens, Shaker A Mousa, Paul J Davis.   

Abstract

Integrin αvβ3 is a heterodimeric structural protein of the plasma membrane that bears a cell surface receptor for thyroid hormone. The functions of this receptor are distinct from those of the classical nuclear receptor (TR) for thyroid hormone. The integrin is expressed primarily by cancer cells, dividing endothelial and vascular smooth muscle cells, and osteoclasts. The hormone receptor on αvβ3 enables L-thyroxine (T(4)) and 3, 5, 3'-triiodo-L-thyronine (T(3)) to stimulate cancer cell proliferation and angiogenesis and to regulate the activity of certain membrane ion pumps. Bound to the receptor, the hormone ligand also stimulates protein trafficking within the cell. A deaminated derivative of T(4), tetraiodothyroacetic acid (tetrac), blocks binding and actions of T(4) and T(3) at the receptor on αvβ3; tetrac also has anti-proliferative actions at the integrin thyroid hormone receptor beyond the effects of antagonizing actions of agonist thyroid hormone analogues at the receptor. The structure-activity relationships of hormone analogues at the receptor have been computer-modeled and indicate that the receptor includes a site that binds T(3) and a site that binds both T(4) and T(3). Mathematical modeling of the kinetics of hormone-binding also suggests the existence of two sites. Cell proliferation is modulated from the T(4)/T(3) site. Tetrac has been re-formulated as a nanoparticle (nanotetrac) that acts exclusively at the αvβ3 receptor and does not enter cells. Nanotetrac disrupts expression of genes in multiple cancer cell survival pathways. The tetrac formulations block human cancer cell proliferation in vitro and in tumor xenografts. Nanotetrac and tetrac inhibit the pro-angiogenic actions in vitro of vascular endothelial growth factor, basic fibroblast factor, and other growth factors. Thus, the receptor described on integrin αvβ3 for T(4) and T(3), the function of which is materially affected by tetrac and nanotetrac, provides insight into tumor cell biology and vascular biology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524387

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  17 in total

Review 1.  Nongenomic actions of thyroid hormone.

Authors:  Paul J Davis; Fernando Goglia; Jack L Leonard
Journal:  Nat Rev Endocrinol       Date:  2015-12-15       Impact factor: 43.330

2.  Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study.

Authors:  Aleck Hercbergs; Rebecca E Johnson; Osnat Ashur-Fabian; David H Garfield; Paul J Davis
Journal:  Oncologist       Date:  2014-11-19

Review 3.  Small molecule hormone or hormone-like ligands of integrin αVβ3: implications for cancer cell behavior.

Authors:  Paul J Davis; Shaker A Mousa; Vivian Cody; Heng-Yuan Tang; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2013-08-14       Impact factor: 3.869

4.  Molecular basis for certain neuroprotective effects of thyroid hormone.

Authors:  Hung-Yun Lin; Faith B Davis; Mary K Luidens; Shaker A Mousa; James H Cao; Min Zhou; Paul J Davis
Journal:  Front Mol Neurosci       Date:  2011-10-14       Impact factor: 5.639

5.  Combined QM/MM study of thyroid and steroid hormone analogue interactions with αvβ3 integrin.

Authors:  Marek Freindorf; Thomas R Furlani; Jing Kong; Vivian Cody; Faith B Davis; Paul J Davis
Journal:  J Biomed Biotechnol       Date:  2012-04-02

Review 6.  Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis.

Authors:  Paul J Davis; Hung-Yun Lin; Thangirala Sudha; Murat Yalcin; Heng-Yuan Tang; Aleck Hercbergs; John T Leith; Mary K Luidens; Osnat Ashur-Fabian; Sandra Incerpi; Shaker A Mousa
Journal:  Onco Targets Ther       Date:  2014-09-18       Impact factor: 4.147

Review 7.  Recurrence of differentiated thyroid carcinoma during full TSH suppression: is the tumor now thyroid hormone dependent?

Authors:  Paul J Davis; Aleck Hercbergs; Mary K Luidens; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2014-10-08       Impact factor: 3.869

8.  Comparative Study of Alterations in Tri-iodothyronine (T3) and Thyroxine (T4) Hormone Levels in Breast and Ovarian Cancer.

Authors:  Mahmood Rasool; Muhammad Imran Naseer; Kalsoom Zaigham; Arif Malik; Naila Riaz; Rabail Alam; Abdul Manan; Ishfaq Ahmed Sheikh; Muhammad Asif
Journal:  Pak J Med Sci       Date:  2014 Nov-Dec       Impact factor: 1.088

Review 9.  Direct effects of thyroid hormones on hepatic lipid metabolism.

Authors:  Rohit A Sinha; Brijesh K Singh; Paul M Yen
Journal:  Nat Rev Endocrinol       Date:  2018-02-23       Impact factor: 43.330

10.  Selective thyroid hormone receptor modulators.

Authors:  Girish Raparti; Suyog Jain; Karuna Ramteke; Mangala Murthy; Ravi Ghanghas; Sunita Ramanand; Jaiprakash Ramanand
Journal:  Indian J Endocrinol Metab       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.